The Novel Application of Surgiflo and Successful Hemostasis of Refractory Intrapulmonary Hemorrhage in Extracorporeal Membrane Oxygenation.

IF 2.7 Q4 Medicine

Critical care explorations Pub Date : 2025-08-06 eCollection Date: 2025-08-01 DOI:10.1097/CCE.0000000000001301

Syed H Haq, Riley Pulver, Hoshimjon Begmatov, Candace Downing, Amanda Laird, Sandeep M Patel, Sreenivasa Chanamolu, William Cole

{"title":"The Novel Application of Surgiflo and Successful Hemostasis of Refractory Intrapulmonary Hemorrhage in Extracorporeal Membrane Oxygenation.","authors":"Syed H Haq, Riley Pulver, Hoshimjon Begmatov, Candace Downing, Amanda Laird, Sandeep M Patel, Sreenivasa Chanamolu, William Cole","doi":"10.1097/CCE.0000000000001301","DOIUrl":null,"url":null,"abstract":"Background: Intrapulmonary hemorrhage (IPH) is a life-threatening condition associated with specific risk factors including prolonged mechanical ventilation, therapeutic anticoagulation, and notably, mechanical circulatory support (MCS). MCS creates a constellation of conditions that predispose patients to IPH. Given the need for systemic anticoagulation and concomitant critical illness, managing IPH can be challenging. Consequently, extracorporeal membrane oxygenation (ECMO) is accompanied by an increased mortality rate.Case summary: We present a case of a patient on ECMO complicated by severe intrapulmonary bleeding refractory to conventional therapies, but responded to the novel application of Surgiflo (a hemostatic matrix) to achieve hemostasis.Conclusions: Endobronchial application of Surgiflo provides a viable option to manage refractory IPH.","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":"7 8","pages":"e1301"},"PeriodicalIF":2.7000,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330348/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical care explorations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CCE.0000000000001301","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Intrapulmonary hemorrhage (IPH) is a life-threatening condition associated with specific risk factors including prolonged mechanical ventilation, therapeutic anticoagulation, and notably, mechanical circulatory support (MCS). MCS creates a constellation of conditions that predispose patients to IPH. Given the need for systemic anticoagulation and concomitant critical illness, managing IPH can be challenging. Consequently, extracorporeal membrane oxygenation (ECMO) is accompanied by an increased mortality rate.

Case summary: We present a case of a patient on ECMO complicated by severe intrapulmonary bleeding refractory to conventional therapies, but responded to the novel application of Surgiflo (a hemostatic matrix) to achieve hemostasis.

Conclusions: Endobronchial application of Surgiflo provides a viable option to manage refractory IPH.

Abstract Image

查看原文本刊更多论文

体外膜氧合治疗难治性肺内出血手术止血的新应用。

背景：肺内出血（IPH）是一种危及生命的疾病，与特定的危险因素相关，包括延长机械通气、治疗性抗凝，尤其是机械循环支持（MCS）。MCS产生了一系列使患者易患IPH的条件。考虑到需要全身性抗凝和伴随的危重疾病，管理IPH可能具有挑战性。因此，体外膜氧合（ECMO）伴随着死亡率的增加。病例总结：我们报告了一例在ECMO下合并严重肺内出血的患者，常规治疗难治性，但对Surgiflo（一种止血基质）的新应用有反应。结论：支气管内应用Surgiflo为治疗难治性IPH提供了一个可行的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊